Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into an underwriting agreement …